• Junzo Kigawa
  • Tsunehisa Kaku
  • Toru Sugiyama
  • Steven G. Silverberg


Clear cell carcinoma (CCC) of the ovary has clinical and pathological features distinct from those of other ovarian carcinomas. Most reports of CCC in the literature consist of relatively small numbers of cases. Recently, an international clinical trial for CCC was conducted by the Japan Gynecologic Oncology Group (JGOG) and 652 cases were collected and underwent central pathological review. This Atlas represents the results of that review, and comprises both typical and unusual pathological features.


Ovarian Cancer Epithelial Ovarian Cancer Histological Subtype Clear Cell Carcinoma Increase Body Mass Index 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    International Agency for Research on Cancer.
  2. 2.
    Jemal A, Siegel R, Ward E et al (2007) Cancer statistics. Cancer J Clin 57:43–66CrossRefGoogle Scholar
  3. 3.
    Conte PF, Cianci C, Gadducci A (1999) Update in the management of advanced ovarian carcinoma. Crit Rev Oncol Hematol 32:49–58CrossRefPubMedGoogle Scholar
  4. 4.
    Bast RC Jr, Hennessy B, Mills GB (2009) The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer 9:415–428CrossRefPubMedCentralPubMedGoogle Scholar
  5. 5.
    Winter WE 3rd, Maxwell GL, Tian C et al (2007) Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol 25:3621–3627CrossRefPubMedGoogle Scholar
  6. 6.
    Ozols RF (2002) Future directions in the treatment of ovarian cancer. Semin Oncol 29:32–42CrossRefPubMedGoogle Scholar
  7. 7.
    McGuire V, Jesser CA, Whittemore AS (2002) Survival among U.S. women with invasive epithelial ovarian cancer. Gynecol Oncol 84:399–403CrossRefPubMedGoogle Scholar
  8. 8.
    Gilks CB, Ionescu DN, Kalloger SE et al (2008) Ovarian Cancer Outcomes Unit of the British Columbia Cancer Agency. Tumor cell type can be reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian carcinoma. Hum Pathol 39:1239–1251CrossRefPubMedGoogle Scholar
  9. 9.
    Sugiyama T, Kamura T, Kigawa J et al (2000) Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer 88:2584–2589CrossRefPubMedGoogle Scholar
  10. 10.
    Takano M, Kikuchi Y, Yaegashi N et al (2006) Clear cell carcinoma of the ovary: a retrospective multicentre experience of 254 patients with complete surgical staging. Br J Cancer 94:1369–1374CrossRefPubMedCentralPubMedGoogle Scholar
  11. 11.
    Itamochi H, Kigawa J, Sugiyama T et al (2002) Low proliferation activity may be associated with chemoresistance in clear cell carcinoma of the ovary. Obstet Gynecol 100:281–287CrossRefPubMedGoogle Scholar
  12. 12.
    Itamochi H, Kigawa J, Terakawa N (2008) Mechanisms of chemoresistance and poor prognosis in ovarian clear cell carcinoma. Cancer Sci 99:653–658CrossRefPubMedGoogle Scholar
  13. 13.
    Reed N (2010) Rare and uncommon gynecological cancers, a clinical guide. Springer, Berlin Heidelberg. ISBN:3642134912Google Scholar
  14. 14.
    Kennedy AW, Biscotti CV, Hart WR et al (1989) Ovarian clear cell adenocarcinoma. Gynecol Oncol 32:342–349CrossRefPubMedGoogle Scholar
  15. 15.
    Crozier MA, Copeland LJ, Silva EG et al (1989) Clear cell carcinoma of the ovary: a study of 59 cases. Gynecol Oncol 35:199–203CrossRefPubMedGoogle Scholar
  16. 16.
    Japan Society of Obstetrics and Gynecology (2013) Annual report. Acta Obstetrics et Gynecology Japonica 65:1032Google Scholar
  17. 17.
    Jacoby VL, Fujimoto VY, Giudice LC et al (2010) Racial and ethnic disparities in benign gynecologic conditions and associated surgeries. Am J Obstet Gynecol 202:514–521CrossRefPubMedGoogle Scholar
  18. 18.
    Olsen CM, Nagle CM, Whiteman DC et al (2008) Australian Cancer Study (Ovarian Cancer) and Australian Ovarian Cancer Study Group body size and risk of epithelial ovarian and related cancers: a population-based case-control study. Int J Cancer 123:450–456CrossRefPubMedGoogle Scholar
  19. 19.
    Pfeiffer RM, Park Y, Kreimer AR et al (2013) Risk prediction for breast, endometrial, and ovarian cancer in white women aged 50 years or older: derivation and validation from population-based cohort studies. PLoS Med 10:e1001492CrossRefPubMedCentralPubMedGoogle Scholar
  20. 20.
    Bulun SE (2009) Endometriosis. N Engl J Med 360:268–279CrossRefPubMedGoogle Scholar
  21. 21.
    Pearce CL, Templeman C, Rossing MA, Consortium OCA et al (2012) Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies. Lancet Oncol 13:385–394CrossRefPubMedCentralPubMedGoogle Scholar
  22. 22.
    Mink PJ, Sherman ME, Devesa SS (2002) Incidence patterns of invasive and borderline ovarian tumors among white women and black women in the United States. Results from the SEER Program, 1978–1998. Cancer 95:2380–2389CrossRefPubMedGoogle Scholar
  23. 23.
    Scarfone G, Bergamini A, Noli S et al (2014) Characteristics of clear cell ovarian cancer arising from endometriosis: a two center cohort study. Gynecol Oncol 133:480–484CrossRefPubMedGoogle Scholar
  24. 24.

Copyright information

© Springer Japan 2015

Authors and Affiliations

  • Junzo Kigawa
    • 1
  • Tsunehisa Kaku
    • 2
  • Toru Sugiyama
    • 3
  • Steven G. Silverberg
    • 4
  1. 1.Matsue City HospitalMatsueJapan
  2. 2.Department of Health SciencesDepartment of Health Sciences Graduate School of Medical SciencesFukuokaJapan
  3. 3.Department of Obstetrics and GynecologyIwate Medical University School of MedicineMoriokaJapan
  4. 4.Department of PathologyUniversity of Maryland School of MedicineBaltimoreUSA

Personalised recommendations